Dual inhibition of HSF1 and DYRK2 impedes cancer progression

Abstract Preserving proteostasis is a major survival mechanism for cancer. Dual specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) is a key oncogenic kinase that directly activates the transcription factor heat-shock factor 1 (HSF1) and the 26S proteasome. Targeting DYRK2 has proven to be a tractable strategy to target cancers sensitive to proteotoxic stress; however, the development of HSF1 inhibitors remains in its infancy. Importantly, multiple other kinases have been shown to redundantly activate HSF1 that promoted ideas to directly target HSF1. The eventual development of direct HSF1 inhibitor KRIBB11 suggests that the transcription factor is indeed a druggable target. The current study establishes that concurrent targeting of HSF1 and DYRK2 can indeed impede cancer by inducing apoptosis faster than individual targetting. Furthermore, targeting the DYRK2-HSF1 axis induces death in proteasome inhibitor-resistant cells and reduces triple-negative breast cancer (TNBC) burden in ectopic and orthotopic xenograft models. Together the data indicate that cotargeting of kinase DYRK2 and its substrate HSF1 could prove to be a beneficial strategy in perturbing neoplastic malignancies.

[1]  Yanlong Gu,et al.  Synthesis of N-(4-chlorophenyl) substituted pyrano[2,3-c]pyrazoles enabling PKBβ/AKT2 inhibitory and in vitro anti-glioma activity , 2022, Annals of medicine.

[2]  Albert C. Chen,et al.  Syrbactin-class dual constitutive- and immuno-proteasome inhibitor TIR-199 impedes myeloma-mediated bone degeneration in vivo , 2021, bioRxiv.

[3]  Stephen R. Williams,et al.  A single-cell and spatially resolved atlas of human breast cancers , 2021, Nature Genetics.

[4]  Linda T. Nieman,et al.  Spatially organized multicellular immune hubs in human colorectal cancer , 2021, Cell.

[5]  Jeong-Hwa Lee,et al.  KRIBB11 Induces Apoptosis in A172 Glioblastoma Cells via MULE-Dependent Degradation of MCL-1 , 2021, Molecules.

[6]  Steven L. Chang,et al.  Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma , 2021, Cancer cell.

[7]  L. de la Vega,et al.  Emerging roles of DYRK2 in cancer , 2020, The Journal of biological chemistry.

[8]  J. Dixon,et al.  The stress-responsive kinase DYRK2 activates heat shock factor 1 promoting resistance to proteotoxic stress , 2020, Cell Death & Differentiation.

[9]  R. Carpenter,et al.  AKT1 mediates multiple phosphorylation events that functionally promote HSF1 activation , 2020, bioRxiv.

[10]  R. Müller,et al.  Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma , 2020, Leukemia.

[11]  Edwin F. Juarez,et al.  Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progression , 2019, Proceedings of the National Academy of Sciences.

[12]  A. Rosenwald,et al.  Spectrum and functional validation of PSMB5 mutations in multiple myeloma , 2018, Leukemia.

[13]  J. Dixon,et al.  Ancient drug curcumin impedes 26S proteasome activity by direct inhibition of dual-specificity tyrosine-regulated kinase 2 , 2018, Proceedings of the National Academy of Sciences.

[14]  G. Morgan,et al.  HSF1 Is Essential for Myeloma Cell Survival and A Promising Therapeutic Target , 2018, Clinical Cancer Research.

[15]  F. Feng,et al.  Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer , 2017, npj Breast Cancer.

[16]  Chunhua Wang,et al.  Anticancer activities of harmine by inducing a pro-death autophagy and apoptosis in human gastric cancer cells. , 2017, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[17]  Mariella G. Filbin,et al.  Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq , 2017, Science.

[18]  R. Orlowski,et al.  Proteasome inhibitors in cancer therapy , 2017, Nature Reviews Clinical Oncology.

[19]  Jayme L. Dahlin,et al.  The Essential Medicinal Chemistry of Curcumin , 2017, Journal of medicinal chemistry.

[20]  H. Goldschmidt,et al.  Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study , 2016, Leukemia.

[21]  S. Lonial,et al.  Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation , 2016, Oncotarget.

[22]  J. Dixon,et al.  Site-specific Proteasome Phosphorylation Controls Cell Proliferation and Tumorigenesis , 2015, Nature Cell Biology.

[23]  K. Iwata,et al.  Aneuploidy generates proteotoxic stress and DNA damage concurrently with p53-mediated post-mitotic apoptosis in SAC-impaired cells , 2015, Nature Communications.

[24]  S. Lonial,et al.  When Cancer Fights Back: Multiple Myeloma, Proteasome Inhibition, and the Heat-Shock Response , 2015, Molecular Cancer Research.

[25]  Z. Storchová,et al.  Causes and consequences of protein folding stress in aneuploid cells , 2015, Cell cycle.

[26]  F. Zhan,et al.  Copper–zinc superoxide dismutase-mediated redox regulation of bortezomib resistance in multiple myeloma , 2014, Redox biology.

[27]  N. Gray,et al.  Characterization of WZ4003 and HTH-01-015 as selective inhibitors of the LKB1-tumour-suppressor-activated NUAK kinases , 2013, The Biochemical journal.

[28]  Marc L. Mendillo,et al.  HSF1 Drives a Transcriptional Program Distinct from Heat Shock to Support Highly Malignant Human Cancers , 2012, Cell.

[29]  Marc L. Mendillo,et al.  High levels of nuclear heat-shock factor 1 (HSF1) are associated with poor prognosis in breast cancer , 2011, Proceedings of the National Academy of Sciences.

[30]  D. Han,et al.  KRIBB11 Inhibits HSP70 Synthesis through Inhibition of Heat Shock Factor 1 Function by Impairing the Recruitment of Positive Transcription Elongation Factor b to the hsp70 Promoter* , 2010, The Journal of Biological Chemistry.

[31]  B. Weaver,et al.  Does aneuploidy cause cancer? , 2006, Current opinion in cell biology.